Vitamin K2 stimulates MC3T3-E1 osteoblast differentiation and mineralization through autophagy induction

WEIWEI LI1, SHAOKUN ZHANG1, JIE LIU2, YONGYI LIU1 and QINGWEI LIANG3

1Department of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning 110000; 2Science Experiment Center of China Medical University, Shenyang, Liaoning 110122; 3Department of Sports Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China

Received April 29, 2018; Accepted March 6, 2019

DOI: 10.3892/mmr.2019.10040

Abstract. Vitamin K2 likely exerts its protective effects during osteoporosis by promoting osteoblast differentiation and mineralization. However, the precise mechanism remains to be fully elucidated. Autophagy maintains cell homeostasis by breaking down and eliminating damaged proteins and organelles. Increasing evidence in recent years has implicated autophagy in the development of osteoporosis. The aim of the present study was to verify whether vitamin K2 (VK2) can induce autophagy during the differentiation and mineralization of osteoblasts. In the present study, MC3T3-E1 osteoblasts were treated with various doses of VK2 (10^{-4}-10^{-3} M) for 1-5 days. The results revealed no cytotoxicity at concentrations below 10^{-5} M, but cell viability was reduced in a dose-dependent manner at concentrations above 10^{-3} M. Furthermore, MC3T3-E1 osteoblasts were seeded in 6-well plates in complete medium supplemented with dexamethasone, β-glycerophosphate and vitamin C (VC) for osteogenic differentiation. MC3T3-E1 osteoblasts treated with different concentrations (10^{-5}, 10^{-4} and 10^{-3} M) of VK2 for 24 h on days 1, 3, 5 and 7 of the differentiation protocol. It was confirmed that VK2 promoted osteoblast differentiation and mineralization by using alkaline phosphatase (ALP) and alizarin red staining. Using western blotting, immunofluorescence, monodansylcadaverine staining and reverse transcription-quantitative polymerase chain reaction, it was observed that VK2 induced autophagy in osteoblasts. The results revealed that VK2 (1 μM) significantly increased ALP activity and the conversion of microtubule associated protein 1 light chain 3-α (LC3) II to LC3I in MC3T3-E1 osteoblasts (P<0.05) at every time point. The number of fluorescent bodies and the intensity increased with VK2, and decreased following treatment with 3-MA+VK2. There was an increase in the mRNA expression levels of ALP, osteocalcin (OCN) and Runx-related transcription factor 2 in VK2-treated cells (P<0.01). The present study further confirmed the association between autophagy and osteoblast differentiation and mineralization through treatment with an autophagy inhibitor [3-methyladenine (3-MA)]. Osteoblasts treated with 3-MA exhibited significant inhibition of ALP activity and osteogenic differentiation (both P<0.05). In addition, ALP activity and osteogenesis in the VK2+3-MA group was lower compared with VK2-treated cells (P<0.05 for both). The present study confirmed that VK2 stimulated autophagy in MC3T3 cells to promote differentiation and mineralization, which may be a potential therapeutic target for osteoporosis.

Introduction

Osteoporotic fractures are increasingly gaining attention due to their high incidence rates and economic burden (1). Osteoporosis is a pathological condition characterized by a decrease in bone mineral density or bone mass, which can reduce bone strength and lead to fractures. Clinical osteoporosis is classified into two types: Type I, or postmenopausal osteoporosis; and type II, i.e., osteoporosis in the elderly (1,2). Bone homeostasis depends on the synergistic activities of osteoclasts and osteoblasts, and any imbalance between bone formation and resorption may lead to a number of diseases, including osteoporosis, Paget’s bone disease and osteodystrophy (3). Apart from decreased bone mass, osteoporosis is associated with a slower rate of bone differentiation following an increase in the number of adipocytes and osteoclasts, decreased osteoblasts and enhanced bone resorption (4,5). In clinical terms, the prevention of osteoporosis is particularly significant and includes resistance exercises to increase bone density, adequate calcium in the diet, and calcium supplement medications (6). In recent years, vitamin K2 (VK2) has attracted attention as an auxiliary drug for preventing osteoporosis (7).

VK2 is a fat-soluble vitamin that is structurally similar to other members of the same family, including phylloquinone, menaquinones and menadione (7). It is a critical factor in the blood clotting process (8-10), and epidemiological studies have demonstrated that a lack of VK2 may lead to osteoporosis and osteoarthritis in older individuals (10,11). In addition, VK2...
has been clinically utilized to prevent osteoporosis, and likely exerts its protective effects by promoting osteoblast differentiation and mineralization (12-14). However, the precise mechanism remains to be fully elucidated (7).

Increasing evidence in recent years has implicated autophagy in the development of osteoporosis. Autophagy is an essential process that maintains homeostasis in eukaryotic cells by breaking down and eliminating damaged proteins and organelles (15,16). When a cell is subjected to external stress, it may initiate autophagy to adjust to the associated stimulus by degrading cytoplasmic substances to provide energy for cell survival (17,18). Autophagy has a critical role in physiological conditions, and is associated with certain diseases, including cancer, diabetes and leukemia. A lack of autophagy in osteoblasts can decrease mineralizing capacity, and induce an imbalance in the population of osteoblasts and osteoclasts, resulting in a low bone mass phenotype (19). The aim of the present study was to verify whether VK2 is able to promote the differentiation and mineralization of osteoblasts by inducing autophagy.

Materials and methods

Chemical reagents. α-Modification minimum essential medium (α-MEM) was purchased from HyClone (GE Healthcare Life Sciences, Logan, UT, USA). Fetal bovine serum (FBS) was acquired from Clark Bioscience (Claymont, DE, USA). The MTT Cell Proliferation and Cytotoxicity Assay kit was purchased from Nanjing Keygen Biotech Co., Ltd. (Nanjing, China). The Alkaline Phosphatase (ALP) Assay kit was purchased from Nanjing Jincheng Bioengineering Institute (Nanjing, China). VK2, vitamin C (VC), and dexamethasone (Dex) were acquired from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). β-Glycerophosphate and alizarin red were purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). The autophagy inhibitor 3-methylaniline (3-MA) and agonist rapamycin were purchased from Selleck Chemicals (Houston, TX, USA). Rabbit anti-microtubule associated protein 1 light chain 3-α (LC3)b antibody was purchased from Abcam (Cambridge, UK; cat. no. ab192890). Rabbit anti-β-actin antibody and goat anti-rabbit IgG antibody were purchased from BIOSS (Beijing, China; cat. nos. bs-0061R and bs-0295G, respectively). Anti-beclin 1 antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA; cat. no. 3738S) and Cy3-conjugated Affinipure Goat Anti-Rabbit IgG (H+L) was obtained from Wuhan Suying Biotechnology (Wuhan, China; cat. no. SA00009-2).

Cell culture and differentiation. MC3T3-E1 is a preosteoblast cell line. It may be used to study differential and mineral induction in an experimental system that mimics a bone-like extracellular matrix (ECM) environment. The appearance of the ECM is crucial to the bone formation process. The mouse cranial osteoblast (MC3T3-E1 Subclone 14; American Type Culture Collection CRL-2594) cell line was obtained from Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). A subclone with high differentiation potential was derived from the parental cell line for studying critical events during osteoblast differentiation and mineralization. The cells were seeded in 15 cm² flasks in α-MEM containing 1% antibiotics and 10% FBS (complete medium), and the medium was changed every 2 days. Cells were passaged when they reached 90% confluence. For osteogenic differentiation, the osteoblasts were first seeded in 6-well plates at a density of 1×10⁶ cells/well in complete medium and cultured for 3 days until the cells reached 70% confluence. To initiate the differentiation, 3 ml complete medium supplemented with Dex (10⁻⁷ M), β-glycerophosphate (10 mM) and VC (50 µg/ml) was added to each well, and the differentiation medium was replaced every 2 days.

Cell viability assay. The cell viability assay was performed to analyze the possible cytotoxic effects of different concentrations of VK2 (10⁻⁸⁻10⁻³ M) on MC3T3-E1 cells. The MC3T3-E1 osteoblasts were seeded into 96-well plates. When 70% confluence was achieved, cells were treated with VK2 at different concentrations (10⁻⁸⁻10⁻³ M) for different durations (1-5 days). At least six replicates per sample were prepared. The cell viability was measured at 48 h using the MTT Cell Proliferation and Cytotoxicity Assay kit, according to the manufacturer's protocol.

Quantitative assay of ALP activity. MC3T3-E1 osteoblasts were plated in 6-well plates at a density of 2.5x10⁴ cells/well and treated with different concentrations (10⁻⁵, 10⁻⁶ and 10⁻⁷ M) of the drugs (3MA, VK2 and 3MA+VK2; untreated controls were also included) for 24 h during the differentiation protocol, and harvested after 1, 3, 5 and 7 days. Total protein was extracted from the cells using radioimmunoprecipitation assay (RIPA) buffer [300 mM NaCl, 50 mM Tris-HCL (pH 7.6), 0.5% Triton X-100, 2 mM phenylmethylsulfonyl fluoride] and quantified using the bicinchoninic acid (BCA) assay. ALP activity was measured using a fluorescence detection kit per the manufacturer's protocol. The standard curve was plotted using p-nitrophenol, and the ALP activity of each sample was normalized to the total protein concentration.

Mineralization analysis. MC3T3-E1 osteoblasts were treated with the different drugs as described above, during the 7-day differentiation. On the 7th day, the supernatant was discarded, and the cells were washed twice with PBS and fixed with 4% paraformaldehyde at room temperature (20°C) for 5 min. Calcium nodes were stained with 0.1% alizarin red at 37°C for 1 h. For quantitative analysis, cells were destained with ethylpyridinium chloride for 30 min at room temperature and transferred to a 96-well plate to measure the absorbance at 550 nm using a microplate reader.

Western blotting. MC3T3-E1 osteoblasts were seeded into 100 mm dishes and cultured in complete α-MEM to 70% confluence, following which the cells were treated with the different drugs as described above. VK2 was used at the optimal concentration of 10⁻⁷ M (1 µM). Total proteins were extracted following lysis of the cells in RIPA buffer at 4°C for 1 h. The lysates were centrifuged at 20,000 x g for 30 min, and the protein concentration was determined using a BCA protein quantification kit. Equal amounts of protein (30 µg) were loaded into each well of a 7.5-15% SDS-PAGE gel and
Figure 1. Cytotoxic effect of VK2 on MC3T3-E1 cells. Different concentrations of VK2 (10⁻⁴-10⁻⁸ M) were used to stimulate the MC3T3-E1 cells for 1-5 days. Concentrations of VK2 between 10⁻¹-10⁻³ M did not cause cytotoxicity. However, concentrations above 10⁻² M significantly reduced cell viability in a dose-dependent manner. Compared with the control, the concentration of 10⁻¹ M had no significant effect on the cell. The experimental data are expressed as the mean ± standard deviation. Significance analysis of the experimental data for each group was performed using one-way analysis of variance and Tukey’s multiple comparisons test. *P<0.05 vs. control group at 1 day; †P<0.05, ††P<0.001 vs. control group at 3 days; ‡P<0.05, ‡‡P<0.01, ‡‡‡P<0.001 vs. control group at 5 days. VK2, vitamin K2.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). MC3T3-E1 osteoblasts were seeded at a density of 5x10⁴ cells/well in a 6-well plate for 3 days until the cells reached 70% confluency. The cells were treated with the different drugs as described, and total RNA was extracted using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer’s protocol. A total of ~1 µg of RNA was used in the reverse transcription reaction using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocols. For gene-specific primed cDNA synthesis, the reaction was conducted for 60 min at 42°C. Then, for random hexamer primed synthesis, incubate for 5 min at 25°C. RT was terminated by heating at 70°C for 5 min. Real-time PCR was performed using the SYBR Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on the ABI 7500 Fast Real-Time PCR System (Applied Biosystems 7500 System Sequence Detection System, software version 2.6.2; Thermo Fisher Scientific, Inc.). The PCR conditions were as follows: Initial denaturation at 95°C for 15 min, followed by 40 cycles of denaturation at 94°C for 20 sec, annealing at 60°C for 30 sec and extension at 72°C for 60 sec. The primer sequences were as follows: Runt-related transcription factor 2 (Runx2) forward, 5'-CCCTGAAGCTGCACCA CATGT-3'; Runx2 reverse, 5'-TGGA TTGGA TGATGGGGAT-3'; osteocalcin (OCN) forward, 5'- AGCGTTTGGCAGACCTA-3'; OCN reverse, 5'-TACGGC CGGAGTCTTGTCACATCT-3'; β-actin forward, 5'- TTCGGTCCGCTTCCACACC-3'; and β-actin reverse, 5'-GCTT TGCA CATGCCC GGAG-3'.

Statistical analysis. All experiments were repeated at least three times and the results are expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). Different groups were compared by one-way analysis of variance followed by Tukey’s multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.

Results

VK2 is not cytotoxic to MC3T3-E1 cells at concentrations below 10⁻³ M. An MTT assay was used to analyze the possible cytotoxic effects of different concentrations of VK2 (10⁻⁴-10⁻³ M) on MC3T3-E1 cells. The cells were stimulated for different durations (1-5 days). No cytotoxicity was observed at concentrations below 10⁻³ M, but cell viability was reduced in a dose-dependent manner at concentrations above 10⁻³ M. Furthermore, compared with the control group, 10⁻³ M VK2 did not have a significant effect on the induction of differentiation and mineralization. Therefore, all subsequent experiments were performed with VK2 at concentrations between 10⁻⁷ and 10⁻⁵ M (Fig. 1).
VK2 enhances ALP activity and promotes MC3T3-E1 osteoblast differentiation and mineralization. To determine the optimal concentration of VK2 that promotes MC3T3-E1 osteoblast differentiation and mineralization, an ALP assay and alizarin red staining were performed, respectively, following treatment of the cells with 10^{-7}-10^{-5} M VK2 for 1-7 days. Treatment with 1 µM VK2 significantly increased ALP activity, while other concentrations were not notably effective. In addition, maximum ALP activity with 1 µM VK2 was observed on the 5th day (Fig. 2A). Bone formation is accompanied by osteogenic differentiation and mineralization, i.e., calcium deposition. MC3T3-E1 osteoblasts treated with VK2 (1 µM) for 7 days exhibited significant calcium deposition, as detected by alizarin red staining (Fig. 2B and C).

Furthermore, the LC3II/LC3I ratio and Beclin-1 levels were higher on day 5, corresponding to the strongest ALP activity (Fig. 3G). Autophagy was also evaluated using immunofluorescence and MDC staining assays. The number of fluorescent bodies and the intensity increased with VK2 and decreased following treatment with 3-MA+VK2. MDC is a marker for autolysosomes; the results demonstrated that the VK2 group had stronger fluorescence, and the fluorescence intensity of the 3-MA+VK2 group was markedly reduced (Fig. 3H). The inhibitory effect of 3-MA on VK2-induced autophagy was confirmed with the significantly decreased LC3II/LC3I ratio in cells treated with 3-MA, and significantly higher ratio in cells treated with rapamycin. Notably, the conversion rate of LC3II/LC3I in the VK2+3-MA group was lower compared with the VK2 group (Fig. 4A). These results demonstrated that VK2 stimulated autophagy in MC3T3-E1 osteoblasts.
**Figure 3.** VK2 stimulates autophagy in MC3T3-E1 osteoblasts. The degree of autophagy was evaluated on the basis of LC3I to LC3II conversion (LC3II/LC3I).

(A) Treatment with 1 µM VK2 for 0.5-1.5 h steadily increased LC3I conversion rates in MC3T3-E1 osteoblasts over (B) 1, 3, 5 and 7 days. Compared with the untreated control cells, those treated with VK2 for 1 h exhibited a significantly higher degree of autophagy at (C) 1, (D) 3 and (E) 5 days, although not at (F) 7 days. (G) Higher LC3II/LC3I conversion rates were observed on day 5 after 0.5, 1 and 1.5 h of treatment compared with the untreated controls.
LI et al: VITAMIN K2 PROMOTES OSTEOBLAST DIFFERENTIATION BY AUTOPHAGY

3-MA inhibited the mineralization induced by VK2 (Fig. 4D). These results demonstrated that autophagy induced by VK2 stimulation is involved in osteogenic differentiation and mineralization.

Discussion

MC3T3-E1 osteoblasts were used to study the mechanism of VK2-mediated amelioration of osteoporosis.
symptoms, as this cell line is routinely used to study the osteogenic characteristics of bone differentiation and mineralization in vitro. Biomarkers including ALP, RUNX2 and OCN are upregulated in the bone matrix during osteogenic differentiation and mineralization, and are thus used to assess the these processes in in vitro models (20,21). Osteoblasts were stimulated with different concentrations of VK2, and osteogenic differentiation and mineralization were evaluated by ALP activity and alizarin red staining, respectively; the concentration of 1 µM induced the most...
significant effect on osteoblast differentiation. The present results are consistent with previous studies that have correlated VK2 with increased osteoblast differentiation and mineralization (22-24). However, the specific mechanism of VK2 in promoting bone metabolism has not yet been elucidated. It was demonstrated that VK2 induced autophagy during osteoblast differentiation and mineralization using the markers LC3 and beclin 1. Studies have increasingly demonstrated a role for autophagy in the occurrence and development of osteoporosis. Studies on human genome-wide association data report that autophagy-related genes are associated with osteoporosis (15,25). In addition, the degree of autophagy decreases along with the expression of LC3-II, beclin 1 and une-51 like autophagy activating kinase 1, while apoptosis and p62 expression increases during osteoporosis (16,26,27). Decreased autophagy likely promotes osteoporosis by increasing oxidative stress (28,29). Furthermore, certain studies have demonstrated that autophagy is associated with the differentiation of osteoblasts. It has been demonstrated that autophagy-associated proteins are involved in osteoblast differentiation and bone formation, and other studies have reported that autophagy affects osteoblast mineralization and bone cell network structure (30,31). Finally, mouse knockout models of autophagy genes illustrate a significant decrease in trabecular bone volume, trabecular number and trabecular thickness (30,32). The present study also confirmed that VK2 may stimulate autophagy in MC3T3 cells to promote differentiation and mineralization. The use of MC3T3 cells is the primary limitation of the present study; these cells are appropriate for the purpose of this research and numerous studies have used MC3T3-E1 to assess differentiation and mineralization (33-36). However, there are limitations associated with performing experiments with a single cell line. The present results may be confirmed by using an additional cell line, such as mesenchymal stem cells, and additional factors may be used to evaluate autophagy in the future, including other types of autophagy inhibitors to exclude off-target effects, and in vivo experiments. Finally, the specific pathways associated with autophagy were completely explored. Therefore, more in-depth mechanistic studies are required.

In conclusion, the present findings indicated that VK2 promotes autophagy during the differentiation and mineralization of osteoblasts, which may be a potential therapeutic target for osteoporosis.

Acknowledgements
Not applicable.

Funding
This study was supported by the Science and Technology Project of Shenyang (grant no. F16-102-4-00).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
WL and QL conceived and designed the study. WL, SZ and YL performed the experiments. WL and JL analyzed the data. WL was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Tella SH and Gallagher JC: Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142: 155-160, 2014.
2. Glaser DL and Kaplan FS: Osteoporosis. Definition and clinical presentation. Spine (Phila Pa 1976) 22 (24 Suppl): 12S-16S, 1997.
3. Edwards MH, Dennison EM, Aihie Sayer A, Fielding R and Cooper C: Osteoporosis and sarcoptenias in older age. Bone 80: 126-130, 2015.
4. Diab DL and Watts NB: Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes 20: 501-509, 2013.
5. Clarke BL: Anti-sclerostin antibodies: Utility in treatment of osteoporosis. Maturitas 78: 199-204, 2014.
6. Levine JP: Identification, diagnosis, and prevention of osteoporosis. Am J Manag Care 17 (Suppl 6): S170-S176, 2011.
7. Palermo A, Tuccinardi D, D’Onofrio L, Watanabe M, Maggi D, Maurizi AR, Greto V, Buzzetti R, Napoli N, Pozzilli P and Manfrini S: Vitamin K and osteoporosis: Myth or reality? Metabolism 70: 57-71, 2017.
8. Nelsesuen GL, Zytkovicz TH and Howard JB: The mode of action of vitamin K. Identification of gamma-carboxyglutamylc acid as a component of prothrombin. J Biol Chem 249: 6347-6350, 1974.
9. Stenflo J, Fernlund P, Egan W and Roepstorff P: Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 71: 2730-2733, 1974.
10. Berkner KL: The vitamin K-dependent carboxylase. Annu Rev Nutr 25: 127-149, 2005.
11. Hauschka PV, Lian JB and Gallop PM: Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72: 3925-3929, 1975.
12. Coutu DL, Wu JH, Monette A, Rivard GE, Blostein MD and Galipeau J: Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J Biol Chem 283: 17991-18001, 2008.
13. Robinacci A: Expanding the functional spectrum of vitamin K in bone. Focus on: -Vitamin K promotes mineralization, osteoblast to osteocyte transition, and an anti-catabolic phenotype by (gamma)-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol 297: C1336-C1338, 2009.
14. Atkins GJ, Welldon KJ, Wijenayaka AR, Bonewald LF and Findlay DM: Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an antitrophic phenotype by (gamma)-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol 297: C1358-C1367, 2009.
15. Pierrefite-Carle V, Santucci-Darmanin S, Breuil V, Camuzard O and Carle GF: Autophagy in bone: Self-eating to stay in balance. Ageing Res Rev 24: 206-217, 2015.
16. Parzych KR and Klionsky DJ: An overview of autophagy: Morphology, mechanism, and regulation. Antioxid Redox Signal 20: 460-473, 2014.
17. White E, Mehnert JM and Chan CS: Autophagy, Metabolism, and Cancer. Clin Cancer Res 21: 5037-5046, 2015.
18. Mizushima N and Levine B: Autophagy in mammalian development and differentiation. Nat Cell Biol 12: 823-830, 2010.
19. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.
20. Yamaguchi M: The role of regucalcin in bone homeostasis: Involvement as a novel cytokine. Integr Biol (Camb) 6: 258-266, 2014.
21. Raouf A and Seth A: Ets transcription factors and targets in osteogenesis. Oncogene 19: 6455-6463, 2000.
22. Yamaguchi M and Weitzmann MN: Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation. Int J Mol Med 27: 3-14, 2011.
23. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B and Inoue S: Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol 39: 239-247, 2007.
24. Zhang YL, Yin JH, Ding H, Zhang W, Zhang CQ and Gao YS: Protective effect of VK2 on glucocorticoid-treated MC3T3-E1 cells. Int J Mol Med 39: 160-166, 2017.
25. Nollet M, Santucci-Darmanin S, Breuil V, Al-Sahlanee R, Cros C, Topi M, Mornier D, Samson M, Pagnotta S, Cailleteau L, et al: Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy 10: 1965-1977, 2014.
26. Pan F, Liu XG, Guo YF, Chen Y, Dong SS, Qiu C, Zhang ZX, Zhou Q, Yang TL, Guo Y, et al: The regulation-of-autophagy pathway may influence Chinese stature variation: Evidence from elder adults. J Hum Genet 55: 441-447, 2010.
27. JiKA RL, Weinstein RS, Parfitt AM and Manolagas SC: Quantifying osteoblast and osteocyte apoptosis: Challenges and rewards. J Bone Miner Res 22: 1492-1501, 2007.
28. Li L, Tan J, Miao Y, Lei P and Zhang Q: ROS and Autophagy: Interactions and molecular regulatory mechanisms. Cell Mol Neurobiol 35: 615-621, 2015.
29. Liu F, Fang F, Yuan H, Yang D, Chen Y, Williams L, Goldstein SA, Krebsbach PH and Guan JL: Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res 28: 2414-2430, 2013.
30. Xi G, Rosen CJ and Clemmons DR: IGF-I and IGFBP-2 stimulate AMPK activation and autophagy, which are required for osteoblast differentiation. Endocrinology 157: 268-281, 2016.
31. Chang KH, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt RG, Weillendorf AM, Hill SE, Watkins M, Gonzalez-Nieto D, et al: p62 is required for stem cell/progenitor retention through inhibition of IKK/NF-kB/Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Rep 9: 2084-2097, 2014.
32. Jilka RL, Weinstein RS, Parfitt AM and Manolagas SC: Enhanced osteogenic differentiation of MC3T3-E1 on rhBMP-2-immobilized titanium via click reaction. Carbohydr Polym 103: 170-178, 2014.
33. He Y, Wang S, Mu J, Dai L, Zhang Z, Sun Y, Shi W and Ge D: Synthesis of polypryrole nanowires with positive effect on MC3T3-E1 cell functions through electrical stimulation. Mater Sci Eng C Mater Biol Appl 71: 43-50, 2017.
34. Mu W, Wang Z, Ma C, Jiang Y, Zhang N, Hu K, Li L, and Wang Z: Metformin promotes the proliferation and differentiation of murine preosteoblast by regulating the expression of sirt6 and ocl4. Pharmacol Res 129: 462-474, 2018.